This study is not yet accepting patients

Pain Related to Local Anesthetic Administration for Nexplanon Placement

a study on Pain

Summary

Eligibility
for females ages 18-50 (full criteria)
Healthy Volunteers
healthy people welcome
Dates
study started
completion around
Principal Investigator
by Sheila Mody, MD, MPH

Description

Summary

This research study is being conducted to see if using buffered lidocaine for Nexplanon placement decreases pain associated with administering local anesthesia compared to unbuffered lidocaine, which is currently used in clinic. Lidocaine is used to stop pain in the nerve fibers in order to decrease pain at the time of the procedure. We want to find out if using buffered lidocaine will decrease discomfort at the time of receiving local anesthesia for Nexplanon insertion.

Official Title

Pain Related to Local Anesthetic Administration for Nexplanon Placement: A Randomized Control Trial of Buffered Lidocaine

Keywords

Pain Related to Local Anesthetic Administration for Nexplanon Placement, Lidocaine, we will prepare 3cc of buffered lidocaine consisting of 2.7cc of 1% lidocaine and 0.3cc of 8.4% sodium bicarbonate, Unbuffered lidocaine

Eligibility

You can join if…

Open to females ages 18-50

  • Ability to provide informed consent
  • Women, aged 18-50 who are English or Spanish speaking who present for Nexplanon placement for contraception
  • Participants must not have a past medical history of substance use disorders, pain disorders, use of pain medications or are found to be pregnant

You CAN'T join if...

  • Current use of pain medication prior to procedure
  • Diagnosed chronic pain condition
  • Pregnancy
  • Known allergic reactions to components of the local anesthetic
  • History of Nexplanon placement
  • Current substance use or history of substance use
  • Known contraindications to Nexplanon, such as history of breast cancer, Systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies, unexplained vaginal bleeding, and liver conditions, including hepatocellular adenoma, malignant liver tumor, and decompensated cirrhosis.

Lead Scientist at UCSD

  • Sheila Mody, MD, MPH
    Professor Of Clinical, Ob/Gyn & Reproductive sciences, Vc-health Sciences-schools. Authored (or co-authored) 56 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT07008222
Study Type
Interventional
Participants
Expecting 68 study participants
Last Updated